{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:56:48Z","timestamp":1777561008714,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,12,11]],"date-time":"2007-12-11T00:00:00Z","timestamp":1197331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The development of an inhibitor against factor VIII (FVIII) is a serious complication in children with haemophilia A. Immune tolerance induction (ITI) therapy is generally considered to be the best approach to eradicate the inhibitor. In this paper, the low\u2010dose (\u226450\u2003IU kg<jats:sup>\u22121<\/jats:sup> twice or three times weekly with plasma\u2010derived factor concentrates) ITI regimen used in Turkey is discussed. This regimen was given to 21 haemophilia A patients with high titer inhibitors. The median age at the beginning of ITI was 9\u2003years and exposure days were 25. The median pre\u2010ITI historical peak inhibitor titer, and inhibitor titer when ITI started were 80\u2003BU (range 6.0\u2013517), 19.2\u2003BU (range 3.6\u2013515), respectively. Complete immune tolerance was defined as the time at which at least two negative inhibitor assays was obtained with no anamnestic response. Our two cases were not reached in follow\u2010up period. Immune tolerance could be achieved in 5 of 19 (26.3%) patients within a median time of 6\u2003months. Partial tolerance was obtained in 7 patients while treatment failed in spite of significant decreased inhibitor levels in the other patients. A relapse developed in one immune\u2010tolerized patient, one year later. The level of inhibitor titer at the beginning of ITI (\u226410\u2003BU), the pre\u2010ITI historical peak inhibitor titer (&lt;50\u2003BU), and the time between the first diagnosis inhibitor to starting ITI (&lt;12\u2003months) were main factors in the success (complete or partial tolerance) of ITI. In conclusion, the outcome of low\u2010dose ITI protocol was not satisfactory in this retrospective study.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2007.01621.x","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T07:04:32Z","timestamp":1204268672000},"page":"315-322","source":"Crossref","is-referenced-by-count":21,"title":["Low\u2010dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors"],"prefix":"10.1111","volume":"14","author":[{"given":"A.","family":"UNUVAR","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"KAVAKLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"BAYTAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"KAZANCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"SAYLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"OREN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"CELKAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"GURSEL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,12,11]]},"reference":[{"key":"e_1_2_7_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01359.x"},{"key":"e_1_2_7_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01362.x"},{"key":"e_1_2_7_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01363.x"},{"key":"e_1_2_7_2_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00311.x"},{"key":"e_1_2_7_2_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9821"},{"key":"e_1_2_7_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01161.x"},{"key":"e_1_2_7_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06087.x"},{"key":"e_1_2_7_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.421"},{"key":"e_1_2_7_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01497.x"},{"key":"e_1_2_7_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90871-6"},{"key":"e_1_2_7_2_12_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0038-1661062","article-title":"The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in hemophilia A","volume":"51","author":"Aznar JA","year":"1984","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_2_13_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1988.03720010043038","article-title":"Induction of immune tolerance to factor VII in hemophiliacs with inhibitors","volume":"259","author":"Ewing NP","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_7_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198804143181503"},{"key":"e_1_2_7_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199221000-00013"},{"key":"e_1_2_7_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01346.x"},{"key":"e_1_2_7_2_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.983.983"},{"key":"e_1_2_7_2_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00379.x"},{"key":"e_1_2_7_2_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-37941"},{"key":"e_1_2_7_2_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00781.x"},{"key":"e_1_2_7_2_21_2","first-page":"206","volume-title":"Activated Prothrombin Complex Concentrates","author":"Stenbjerg S","year":"1982"},{"key":"e_1_2_7_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04763.x"},{"key":"e_1_2_7_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00141.x"},{"key":"e_1_2_7_2_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00171.x"},{"issue":"4","key":"e_1_2_7_2_25_2","first-page":"62","article-title":"Immunetolerance as treatment of alloantibodies to factor VIII in hemophiliacs. The International Registry of Immunetolerance Protocols","volume":"31","author":"Mariani G","year":"1994","journal-title":"Semin Hematol"},{"key":"e_1_2_7_2_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000056710"},{"key":"e_1_2_7_2_27_2","first-page":"45","article-title":"The German registry of immune tolerance treatment in hemophilia \u2013 1999 update","volume":"85","author":"Lenk H","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_7_2_28_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DiMichele DM","year":"2002","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_2_29_2","first-page":"1186","article-title":"Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"Mariani G","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_7_2_30_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0038-1648828","article-title":"Immune tolerance in hemophilia \u2013 principal results from the international registry","volume":"72","author":"Mariani G","year":"1994","journal-title":"J Thromb Haemost"},{"issue":"1","key":"e_1_2_7_2_31_2","first-page":"156a","article-title":"Analysis of the North American immune tolerance registry (NAITR) 1993\u201397 current practice implications","volume":"90","author":"DiMichele DM","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_2_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000056713"},{"key":"e_1_2_7_2_33_2","first-page":"558","article-title":"Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors","volume":"91","author":"Rocino A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_2_34_2","first-page":"782","article-title":"Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors","volume":"72","author":"Ehrenforth S","year":"1994","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01167.x"},{"key":"e_1_2_7_2_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00036.x"},{"key":"e_1_2_7_2_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167660.30886.e9"},{"key":"e_1_2_7_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02127.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2007.01621.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2007.01621.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T05:52:44Z","timestamp":1697176364000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2007.01621.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,11]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1365-2516.2007.01621.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2007.01621.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,11]]}}}